BIND Therapeutics

Bind Therapeutics (BIND) is a biopharmaceutical company developing therapeutic targeted nanoparticles. Leveraging its proprietary Medicinal Nanoengineering™ platform, BIND will produce best in class drugs by drastically enhancing the performance of development candidates or marketed drugs. BIND’s current development efforts focus on oncology, cardiovascular disorders, inflammatory disease and RNAi therapeutics. Lead program BIND-014 targets a surface protein upregulated in solid tumors and is planned to enter clinical development by end 2010.

BIND was incorporated in 2007 in Cambridge, MA, based on the work of two pioneers in the field of therapeutic nanoparticles, Dr. Robert Langer (MIT) and Dr. Omid Farokhzad (Harvard Medical School).


Recent News

March 11, 2015
BIND Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results

 
March 10, 2015
BIND Therapeutics Appoints Andrew Hirsch as Acting President and Chief Executive Officer

 
November 6, 2014
BIND Therapeutics Announces Agreement with Merck to Develop Targeted Accurin™ Nanomedicines for Oncology

 
June 19, 2014
Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant

 
September 19, 2013
BIND Therapeutics Announces Pricing of Initial Public Offering

 
August 27, 2013
BIND Recognized by the World Economic Forum as a Technology Pioneer

 
August 19, 2013
BIND Doses First Patient in a Phase 2 Clinical Study of BIND-014 in Prostate Cancer

 
August 12, 2013
BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering

 
April 22, 2013
BIND Therapeutics and AstraZeneca Announce Worldwide Development and Commercialization Agreement for Cancer Nanomedicine

 
April 3, 2013
BIND Therapeutics Announces Global Collaboration with Pfizer to Develop and Commercialize Multiple Accurins

 
January 8, 2013
BIND Biosciences and Amgen Sign Agreement For The Worldwide Development and Commercialization of a Kinase Inhibitor Nanomedicine

 
September 20, 2012
BIND Is Granted Five U.S. Patents Covering BIND-014 and Accurin(TM) Platform

 
July 16, 2012
BIND Biosciences appoints Andrew J. Hirsch as Chief Financial Officer

 
June 22, 2012
BIND Biosciences CEO Scott Minick and Founder Omid Farokhzad Win Ernst & Young New England Entrepreneur of the Year Award

 
April 4, 2012
BIND Biosciences Presents Clinical Data on BIND-014 Promising Anti-tumor Effects in Patients with Advanced or Metastatic Cancers

 
October 27, 2011
BIND Announces New $47.25 Million Financing To Accelerate Multi-Product Pipeline

 
April 6, 2011
BIND Biosciences Receives 2011 Edison Award

 
February 23, 2011
BIND Biosciences named one of MIT's Technology Review 2011 TR50 - second year in a row

 
February 11, 2011
BIND Biosciences featured in the London Times

 
January 7, 2011
BIND Biosciences Initiates Phase 1 Clinical Study of BIND-014

 
June 29, 2010
BIND Biosciences Secures $12.4 Million Financing

 


Company Info
 
Country: USA
Industry:    Biotech
Sector: biotechnology
Status: Unrealized
Vehicle: Endeavour II LP


Key persons
 Scott Minick, CEO; Dr. Robert Langer, co-founder; Dr. Omid Farokhzad, co-founder


Company website
 www.bindtherapeutics.com


Endeavour Vision Team
 
Sven Lingjaerde
Daniel Bertholet
© Endeavour Vision SA 2006-2017 Terms & Conditions